ATOPIC DERMATITIS

This study tests an oral medication called KT-621 for people aged 12 to 75 with moderate-to-severe atopic dermatitis (eczema). The goal is to see if it reduces skin redness, itching, and affected body area compared to a placebo. The trial lasts 16 weeks with a follow-up open-labe…

This Phase 2 trial tests whether a stem cell therapy called ADSTEM can safely and effectively treat moderate-to-severe atopic dermatitis (eczema). About 118 adults with long-lasting eczema that hasn't responded well to standard creams will receive either ADSTEM stem cells or a pl…

This early-stage trial is testing a combination of two experimental drugs, APG777 and APG990, in 86 adults with moderate-to-severe atopic dermatitis (eczema). The main goal is to check safety and how the drugs move through the body, comparing them to the existing treatment Dupixe…

This study looks at the long-term safety of dupilumab (Dupixent) in children aged 6 months to 18 years with atopic dermatitis (eczema). About 880 kids who were in earlier dupilumab studies will continue treatment. Researchers will track side effects and check if a pre-filled pen …

This Phase 2a study tests a new drug called GIA632 in 34 adults with moderate to severe atopic dermatitis (eczema). The goal is to see if it safely improves skin symptoms compared to a placebo. Participants are randomly assigned to receive either the drug or a placebo, and neithe…

This study tests a new drug called Afimkibart (RO7790121) in 160 adults with moderate to severe atopic dermatitis (eczema). Participants receive either the drug or a placebo as a shot under the skin. The main goal is to see if the drug improves eczema symptoms by at least 75% aft…

This study looks at the long-term safety and effectiveness of lebrikizumab for children aged 6 months to under 18 years with moderate-to-severe atopic dermatitis (eczema). About 310 participants who completed a prior study will receive lebrikizumab for up to 116 weeks. The goal i…

This study looks at the long-term safety and tolerability of a drug called rocatinlimab for people with moderate-to-severe atopic dermatitis (eczema). It involves over 2,600 adults and teenagers who have already completed a previous rocatinlimab study. Researchers will monitor si…

This study tests an experimental drug called TRIV-509 in 95 adults with moderate to severe atopic dermatitis (eczema). Participants receive four doses of either TRIV-509 or a placebo, then switch to the other group. The goal is to see if TRIV-509 improves eczema symptoms and is s…

This study tests whether baricitinib, an oral anti-inflammatory drug, is safe and effective for children aged 2 to 17 with moderate to severe atopic dermatitis (eczema). About 516 participants will receive either baricitinib or a placebo, along with standard topical steroids. The…

This study tests an experimental injection called TQH2722 in 500 adults with moderate to severe eczema (atopic dermatitis). The goal is to see if it can significantly reduce skin redness, itching, and rash compared to a placebo. Participants receive either the drug or a dummy sho…

This study tests whether ATI-045 can safely reduce eczema symptoms like redness, itching, and skin patches in people with moderate-to-severe disease. About 110 adults who haven't had success with topical treatments will receive either the drug or a placebo. The main goal is to se…

This study tracks the safety and effectiveness of CIBINQO (abrocitinib) tablets in over 1,100 Japanese patients with atopic dermatitis (eczema) under real-world medical practice. Researchers will monitor side effects, treatment dropouts, and skin clearance over time. The goal is …

This study tests whether upadacitinib (Rinvoq), a daily pill already used in older patients, can safely improve moderate to severe eczema in children aged 2 to 11 in Japan. About 99 kids will receive either the drug or a placebo, plus a steroid cream, for up to a year. Researcher…

This study tests a drug called lutikizumab for people with moderate to severe atopic dermatitis (eczema) that hasn't improved with standard treatments. About 80 participants will receive either the drug or a placebo for 16 weeks, then everyone gets the drug for another 32 weeks. …

This study follows about 772 teenagers and adults with moderate to severe eczema who are taking upadacitinib (Rinvoq) as prescribed by their doctor. Researchers want to see how well the drug controls the disease over two years in everyday medical practice. Participants will have …

This study tests whether adding narrowband UVB phototherapy (a type of light treatment) to optimized topical therapy (creams, ointments, and skin care advice) helps adults with moderate atopic eczema more than topical therapy alone. About 316 adults whose eczema is not well contr…

This study tests a drug called lebrikizumab in children aged 6 months to 18 years with moderate-to-severe eczema (atopic dermatitis). The goal is to see if it improves skin condition and reduces itching compared to a placebo. About 367 participants will receive either the drug or…

This study looks at how well methotrexate, a drug often used for arthritis, works for people with hand eczema. Researchers will track 50 patients to see if their skin improves and how their quality of life changes. The goal is to find better ways to manage this chronic skin condi…

This study tests a new oral medication, jaktinib, for adults with moderate to severe atopic dermatitis (eczema). About 443 participants will receive either jaktinib or a placebo to see if it improves skin symptoms like redness and itching. The goal is to find a safe and effective…

This study tests whether a daily pill called upadacitinib, used with a steroid cream, can safely reduce eczema symptoms like itching and redness in teens and adults with moderate-to-severe disease. About 1,500 participants took the pill or a placebo for 16 weeks. The main goals w…

This phase 3 trial tests a drug called lebrikizumab, given as a shot, for people with moderate-to-severe eczema that hasn't improved with standard creams. Some participants also use a steroid cream. The study involves 301 adults and lasts about 62 weeks. Researchers are checking …

This study tests a new drug called CM310 in 180 teenagers with moderate-to-severe atopic dermatitis (eczema). The goal is to see if the drug is safe and helps clear skin. Participants receive the drug and are monitored for side effects and skin improvement over time.

This study looks at whether people with atopic dermatitis (eczema) that has been well-controlled for at least six months can safely take dupilumab less often. About 256 teens and adults will either stick with their usual every-two-week injection or gradually space out doses. The …

This study tests whether using a special skin barrier cream (Epiceram) twice a day, along with a steroid cream at the first sign of eczema, can prevent food allergies in babies who develop eczema by 12 weeks old. The goal is to see if this proactive skin care reduces the number o…

This study tests a prescription cream called ruxolitinib for children and teens (ages 6 to 17) with moderate eczema. The cream is applied to the skin to reduce redness, itching, and rash. Researchers want to see if it works better than a cream with no medicine and check for side …

This early-stage trial tests a new ointment called CU-10101 in 64 people, first in healthy volunteers and then in those with mild to moderate atopic dermatitis (eczema). The main goal is to check safety and how the body handles the drug, with a preliminary look at whether it impr…

This study tests whether ointments made from propolis, a natural substance from honeybees, can improve dry, itchy skin in adults with atopic tendencies. Thirty participants will apply either a propolis ointment or a plain base ointment twice daily for four weeks. Researchers will…

This study tests whether lebrikizumab can reduce itching and skin symptoms in people with moderate eczema who have a high itch burden. About 233 adults and teens will receive the drug for 24 weeks. The main goal is to see if at least 75% of skin symptoms improve or if itch scores…

This study tests an experimental drug called APG777 in 470 adults with moderate-to-severe atopic dermatitis (eczema) that hasn't improved with creams. The goal is to see if the drug safely reduces skin redness, itching, and rash. Participants receive either APG777 or a placebo fo…

This study tests an experimental drug called barzolvolimab in adults with moderate to severe atopic dermatitis (eczema). The goal is to see if it can reduce itching and improve skin condition compared to a placebo. About 131 participants will receive either a low dose, high dose,…

This study tested whether Bodewell eczema products are safe and help improve skin symptoms in adults with atopic dermatitis (eczema). Fifteen participants used the products for 12 weeks. Researchers measured skin clearance and quality of life improvements.

This early study will test a special microbubble bath system (Thera-Clean) on 20 people with certain skin diseases like epidermolysis bullosa, ichthyosis, atopic dermatitis, or psoriasis. The goal is to see if the chemical-free bubbles can clean wounds, reduce itching, and improv…

This study aims to understand inflammation in four chronic skin conditions: vitiligo, psoriasis, eczema (atopic dermatitis), and alopecia areata. Researchers will collect blood and small skin samples from 450 adults to analyze immune cells called T-cells. The goal is to describe …

This study aims to understand how inflammation works in the skin and how certain anti-inflammatory drugs (biologics) affect it. Researchers will create small suction blisters on the skin of healthy volunteers and people with skin conditions, then analyze the fluid and cells. The …

This study enrolls 2500 pregnant women and follows their children from before birth up to age 3 (or 6 for those who continue). Researchers collect biosamples and environmental data to identify early-life markers and biological pathways that lead to food allergy and atopic dermati…

This study follows 456 mothers and their children for 5 years to see if certain chemicals in the mother's blood during pregnancy are linked to the child developing eczema. Researchers will check children's skin regularly and track any eczema diagnosis. The goal is to understand p…

This study looks at skin and blood samples from 505 children with eczema (atopic dermatitis) to find biological markers that explain the disease. Researchers compare these markers to those in adults to see if they are similar. The goal is to better understand what causes eczema i…

This early-stage study tests a new drug called SHR-1819 in 160 healthy adults to see how it enters the body when given with different injection devices. The goal is to compare the drug levels and safety between devices, not to treat any disease. Participants must be 18-55 years o…

This study aims to find specific gene changes (filaggrin mutations) in 300 Latinx adults with eczema. Researchers will use advanced DNA testing to see how these changes relate to the disease. The goal is to better understand eczema in this group, not to test a new treatment.

This study follows 15,000 adults and children with skin conditions like eczema, psoriasis, and vitiligo to see how well current and new treatments work in real doctor visits. It does not test a new drug but instead collects information to help doctors understand which treatments …

This study looks at blood inflammation in people with moderate to severe atopic dermatitis (eczema). Researchers will take blood samples before and after 3 months of treatment to see how immune signals change. The goal is to better understand the immune response in different pati…

This study follows 143 children aged 6 months to 11 years with severe atopic dermatitis (eczema) who are starting treatment with dupilumab in Spain. Researchers will observe how the drug is used in everyday practice, its effectiveness, and any side effects over two years. No extr…

This registry will follow 10,000 adults with atopic dermatitis (eczema) who are already using approved treatments. Researchers will collect data on how well the treatments work and any side effects over time. The goal is to better understand the disease, its complications, and cu…

This study looks at how a new medicine called PF-08049820 changes the way birth control pills, a sedative, and a blood thinner move through the body. It involves 16 healthy adult women who will take the drugs alone and then with PF-08049820. The results will help plan future stud…

This study follows 8,000 children aged 2 to 17 with eczema who have used Elidel cream (pimecrolimus 1%). Over 10 years, researchers track how many develop cancer, especially lymphoma and thyroid cancer. The goal is to see if the cream raises cancer risk. No new treatment is given…